HIV Infections Clinical Trial
Official title:
Single Dose and 14-Day Once or Twice-Daily Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel
Verified date | May 2008 |
Source | CONRAD |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a multi-center, pharmacokinetic study involving a single-dose phase, a wash out
phase and a two-week once or twice-daily dosing phase for each of 49 volunteers.
In the single-dose phase, each volunteer will apply the single dose in the clinic.
Participants will be randomized to have cervicovaginal samples and biopsies collected at one
of seven time-points [0.5, 1, 2, 4, 6, 8, and 24 hour(s)] after the single-dose. Blood
samples will be drawn at 0.5, 1, 2, 4, 6, 8, and 24 hour(s) after the single-dose.
In the two-week phase, the study supplies will be distributed and the participants will be
randomized to apply each dose either once or twice-daily for two weeks. At the one week
follow-up visit a blood sample will be drawn prior to the morning dose to obtain a trough
value and cervicovaginal samples will be collected four hours after the morning dose. At the
two week follow-up visit blood samples will be drawn prior to the morning dose to obtain a
trough value and then at 0.5, 1, 2, 4, 6, 8, and 24 hour(s) from the final morning dose.
Participants will be randomized to have cervicovaginal samples and biopsies collected at
either 4, 8 or 24 hours after the final morning dose.
Up to 10 participants who have completed the first two phases of the study, will be asked to
participate in a third phase to have cervicovaginal samples, biopsies and blood samples
collected 12 hours after a single-dose.
Status | Completed |
Enrollment | 49 |
Est. completion date | April 2008 |
Est. primary completion date | April 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Must be between 18-45 years old, inclusive - Must be in general good health by volunteer history without any clinically significant systemic disease (including liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease) - Must have regular menstrual cycles (minimum of 26 and maximum of 38 days) - Must be at least 2 months since last pregnancy outcome and have had at least two spontaneous menses - Must abstain from sexual activity and use of intravaginal products for 72 hours prior to the start of the single-dose phase and multi-dose phase, for at least one week following vaginal biopsies and for the duration of the study phases - Willingness to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol Exclusion Criteria: - Currently pregnant or at risk for pregnancy (may be using ParagardĀ® IUD, effective barrier method, female sterilization or abstinence, or be sexually active with a vasectomized partner) - Currently breastfeeding or planning to breastfeed during the course of the study - Use of any hormonal contraceptives within 30 days of enrollment - Use of Depo-Provera within 120 days of enrollment History of abnormal Pap smear (by volunteer history) that has not been evaluated and treated, if indicated, according to standard guidelines - Current vaginal or urinary tract infection - Positive test for Neisseria gonorrhea or Chlamydia trachomatis at the time of screening - Positive wet mount for Trichomonas vaginalis at the time of screening or enrollment - Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for a sexually transmitted infection - Current or past use of any anti-retroviral therapies including but not limited to systemic tenofovir (VireadĀ®) - Current or recent drug or alcohol abuse - Current or anticipated use of drugs on a daily basis that may reduce renal function (e.g. acyclovir or ibuprofen) or liver function (e.g. tylenol) - HIV positive at the time of screening - Hepatitis B surface antigen (HBsAg) positive at the time of screening - Grade 1 or higher serum chemistry or complete blood count abnormality in accordance with DAIDS toxicity table values - Abnormal finding on laboratory or physical examination or a medical condition which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data - Participation in any other research study in the 30 days prior to screening and/or plans to participate in any other research study during entire study duration |
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Dominican Republic | Profamilia | Santo Domingo | |
United States | Advances in Health, Inc | Houston | Texas |
United States | University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
CONRAD | Gilead Sciences, International Partnership for Microbicides, Inc. |
United States, Dominican Republic,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Concentration of tenofovir in local genital tract compartments (intraluminal, mononuclear cells and vaginal tissue levels). Concentration (Cmax) and time of maximum concentration (Tmax) of tenofovir in the systemic compartment. | Single dose; two weeks (after once or twice-daily vaginal administration) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |